Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: The Rizzoli experience

Citation
G. Bacci et al., Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: The Rizzoli experience, ONCOL REP, 7(5), 2000, pp. 1129-1133
Citations number
25
Categorie Soggetti
Oncology
Journal title
ONCOLOGY REPORTS
ISSN journal
1021335X → ACNP
Volume
7
Issue
5
Year of publication
2000
Pages
1129 - 1133
Database
ISI
SICI code
1021-335X(200009/10)7:5<1129:LASCFO>2.0.ZU;2-Z
Abstract
Five-hundred and twenty-six patients with nonmetastatic osteosarcoma of the extremities treated at Istituto Ortopedico Rizzoli from 1983 to 1995 with neoadjuvant chemotherapy and limb salvage, were retrospectively studied to evalute the rate of local and systemic control. At a mean follow-up of 9.5 years (3-17), 320 patients remained continuously free of disease and 206 re lapsed. The 5-year disease-free survival and overall survival were 64% and 70% respectively. In patients who relapsed, there were 31 local recurrences (6%). The rate of local failures was significantly higher in the 79 patien ts with inadequate surgical margins (marginal, inralesional, and contaminat ed margins) than in the 486 patients with wide surgical margins (2.6% vs. 2 5.0%; P<0.0001). Twenty-nine of the 31 patients (94%) with local recurrence also had metastases and died of the tumor. In comparison with patients who only had a systemic relapse, patients with local recurrences had a higher rate of metastases located in bones (41% vs. 7%; P<0.001), and a worse post -relapse outcome (5-year overall survival: 6% vs. 24%; P<0.04). We conclude d that in osteosarcoma of the extremity treated with neoadjuvant chemothera py: i) limb salvages procedures do not compromise the outcome of patients, provided the achievement of adequate surgical margins; ii) local recurrence s are a marker either of the inadequacy of local treatment or of the high l ocal and systemic aggressiveness of the tumor.